Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

amarillo biosciences inc. - AIMD

AIMD

Close Chg Chg %
1.98 0.01 0.40%

Closed Market

1.99

+0.01 (0.40%)

Volume: 21.20K

Last Updated:

Dec 26, 2025, 4:00 PM EDT

Trade Now

Company Overview: amarillo biosciences inc. - AIMD

AIMD Key Data

Open

$1.95

 Day Range

1.94 - 1.99

52 Week Range

1.78 - 5.00

 Market Cap

$9.53M

Shares Outstanding

4.81M

 Public Float

1.69M

Beta

2.38

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$4.18

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

24.94K

  

AIMD Performance

1 Week
 
 -7.39%
 
1 Month
 
 -6.95%
 
3 Months
 
 -43.85%
 
1 Year
 
 -13.92%
 
5 Years
 
 N/A
 

AIMD Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About amarillo biosciences inc. - AIMD

Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. Its medtech solutions include COVID-19 Antigen Rapid Test Kit, VOC POCT-Ainos Flora, VOC POCT-Ainos Pen, VOC POCT-CHS430, Very Low-Dose Oral Interferon Alpha, and Synthetic RNA. The company was founded on June 26, 1984 and is headquartered in San Diego, CA.

AIMD At a Glance

Ainos, Inc.
8880 Rio San Diego Drive
San Diego, California 92108
Phone 1-858-869-2986 Revenue 20.73K
Industry Information Technology Services Net Income -14,863,161.00
Sector Technology Services Employees 44
Fiscal Year-end 12 / 2025
View SEC Filings

AIMD Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 209.062
Price to Book Ratio 0.453
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.376
Enterprise Value to Sales 600.161
Total Debt to Enterprise Value 0.965

AIMD Efficiency

Revenue/Employee 471.114
Income Per Employee -337,799.114
Receivables Turnover 370.161
Total Asset Turnover 0.001

AIMD Liquidity

Current Ratio 1.097
Quick Ratio 1.06
Cash Ratio 0.984

AIMD Profitability

Gross Margin -23,317.97
Operating Margin -66,772.155
Pretax Margin -71,698.398
Net Margin -71,702.258
Return on Assets -49.003
Return on Equity -74.383
Return on Total Capital -54.016
Return on Invested Capital -54.161

AIMD Capital Structure

Total Debt to Total Equity 77.338
Total Debt to Total Capital 43.61
Total Debt to Total Assets 41.637
Long-Term Debt to Equity 58.003
Long-Term Debt to Total Capital 32.708
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Amarillo Biosciences Inc. - AIMD

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
594.56K 3.52M 122.11K 20.73K
Sales Growth
+3,489.71% +491.97% -96.53% -83.02%
Cost of Goods Sold (COGS) incl D&A
2.22M 6.93M 5.23M 4.85M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.03M 4.81M 4.85M 4.80M
Depreciation
31.39K 291.71K 328.94K 252.55K
Amortization of Intangibles
2.00M 4.52M 4.52M 4.55M
COGS Growth
+8,430.81% +212.65% -24.53% -7.15%
Gross Income
(1.62M) (3.41M) (5.11M) (4.83M)
Gross Income Growth
-17,126.04% -110.22% -49.81% +5.34%
Gross Profit Margin
-272.69% -96.84% -4,181.56% -23,317.97%
2021 2022 2023 2024 5-year trend
SG&A Expense
2.25M 10.57M 7.81M 9.01M
Research & Development
1.92M 2.03M 7.03M 8.41M
Other SG&A
325.47K 8.54M 782.82K 593.70K
SGA Growth
+56.96% +370.50% -26.06% +15.28%
Other Operating Expense
- - - -
-
Unusual Expense
- - 718.21K 583.96K
-
EBIT after Unusual Expense
(3.87M) (13.98M) (13.64M) (14.43M)
Non Operating Income/Expense
(2.55K) 23.05K 12.28K 179.27K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
18.69K 53.53K 144.19K 616.47K
Interest Expense Growth
+83.44% +186.41% +169.38% +327.53%
Gross Interest Expense
18.69K 53.53K 144.19K 616.47K
Interest Capitalized
- - - -
-
Pretax Income
(3.89M) (14.01M) (13.77M) (14.86M)
Pretax Income Growth
-168.07% -260.19% +1.69% -7.93%
Pretax Margin
-654.04% -397.96% -11,276.33% -71,698.40%
Income Tax
- - 800 800
-
Income Tax - Current - Domestic
- - (1.57M) (128.20K)
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - 1.57M 129.00K
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(3.89M) (14.01M) (13.77M) (14.86M)
Minority Interest Expense
- - - -
-
Net Income
(3.89M) (14.01M) (13.77M) (14.86M)
Net Income Growth
-168.07% -260.19% +1.69% -7.93%
Net Margin Growth
-654.04% -397.96% -11,276.98% -71,702.26%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(3.89M) (14.01M) (13.77M) (14.86M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(3.89M) (14.01M) (13.77M) (14.86M)
EPS (Basic)
-12.8738 -25.6772 -16.8011 -7.8198
EPS (Basic) Growth
+3.59% -99.45% +34.57% +53.46%
Basic Shares Outstanding
302.05K 545.49K 819.62K 1.90M
EPS (Diluted)
-12.8738 -25.6772 -16.8011 -7.8198
EPS (Diluted) Growth
+3.59% -99.45% +34.57% +53.46%
Diluted Shares Outstanding
302.05K 545.49K 819.62K 1.90M
EBITDA
(1.84M) (9.16M) (8.07M) (9.04M)
EBITDA Growth
-28.76% -399.12% +11.95% -12.05%
EBITDA Margin
-308.75% -260.33% -6,606.37% -43,607.89%

Insider Actions for Amarillo Biosciences Inc. - AIMD

Date Name Shares Transaction Value
Mar 12, 2025 Chung Yi Tsai Director 204,400 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.46 per share 94,024.00
Mar 12, 2025 Chun Hsien Tsai CEO, PRESIDENT, CHAIRMAN; Director N/A Conversion of derivative security 0.00
Mar 12, 2025 Wen Han Chang Director 257,733 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.46 per share 118,557.18
Mar 12, 2025 Ting Chuan Lee Director N/A Conversion of derivative security 0.00
Mar 12, 2025 Ting Chuan Lee Director N/A Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Ting Chuan Lee Director 531,432 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.46 per share 244,458.72
Mar 12, 2025 Chung Jung Tsai Director N/A Conversion of derivative security 0.00
Mar 12, 2025 Chung Jung Tsai Director N/A Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Chung Jung Tsai Director 527,900 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.46 per share 242,834.00
Mar 12, 2025 Chung Yi Tsai Director N/A Conversion of derivative security 0.00
Mar 12, 2025 Chung Yi Tsai Director N/A Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Yao Chung Chiang Director 206,400 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.46 per share 94,944.00
Mar 12, 2025 ASE Technology Holding Co., Ltd. 499,377 Open market or private purchase of non-derivative security 0.00
Mar 12, 2025 Christopher Lee CFO N/A Conversion of derivative security 0.00
Mar 12, 2025 Christopher Lee CFO N/A Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Christopher Lee CFO 276,376 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.46 per share 127,132.96
Mar 12, 2025 Pao Sheng Wei Director N/A Conversion of derivative security 0.00
Mar 12, 2025 Pao Sheng Wei Director N/A Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 12, 2025 Pao Sheng Wei Director 204,400 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $0.46 per share 94,024.00
Mar 12, 2025 Yao Chung Chiang Director N/A Conversion of derivative security 0.00

Amarillo Biosciences Inc. in the News